| Gw & Associates/a Wellness Organization, Inc. | |
|
18th Medical Group Unit 5142 Kadena Afb Okinawa Japan Apo AP 96368-5142 | |
| (816) 117-328210 | |
| Not Available |
| Full Name | Gw & Associates/a Wellness Organization, Inc. |
|---|---|
| Speciality | Community/behavioral Health |
| Location | 18th Medical Group Unit 5142, Apo, Armed Forces Pacific |
| Authorized Official Name and Position | Gail Wells (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 3123124289589 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Gw & Associates/a Wellness Organization, Inc. Psc 80 Box 14578 Apo Ap Okinawa KADENA AFB 96367 Ph: () - | Gw & Associates/a Wellness Organization, Inc. 18th Medical Group Unit 5142 Kadena Afb Okinawa Japan Apo AP 96368-5142 Ph: (816) 117-328210 |
| NPI Number | 1376712372 |
|---|---|
| Provider Enumeration Date | 02/22/2008 |
| Last Update Date | 02/24/2011 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376712372 | NPI | - | NPPES |
| 6297 | Other | IL | DASA PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | A62970001A (Illinois) | Primary |
News Archive
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).
Premature infants' immature lungs and frequent dips in blood pressure make them especially vulnerable to a condition called hypoxia in which their tissues don't receive enough oxygen, sometimes leading to permanent brain damage. New animal research suggests that a common practice in caring for these babies might in fact exacerbate this condition, increasing the chances for long-term neurological deficits.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
Epstein-Barr virus (EBV) reactivation resulting from the inflammatory response to coronavirus infection may be the cause of previously unexplained long COVID symptoms - such as fatigue, brain fog, and rashes - that occur in approximately 30% of patients after recovery from initial COVID-19 infection.
Even early stages of kidney disease come with steep medical costs, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The study found that expenses related to moderate chronic kidney disease cost Medicare tens of billions of dollars each year.
› Verified 7 days ago